Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. Its lead candidate, eganelisib (IPI-549), is a potentially first-in-class, oral, once-daily selective inhibitor of PI3K-gamma that reprograms tumor-associated macrophages (M2 macrophages) to perform anti-tumor functions, thereby reducing immune suppression and encouraging immune activation. The company ran Phase 2 trials including MARIO-275 in urothelial cancer and MARIO-3 in triple-negative breast cancer. Infinity was listed on Nasdaq under ticker INFI and filed for Chapter 11 bankruptcy in October 2023.